Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. El Mahdaoui S, Pontieri L, Romme Christensen J, Alabdalridha H, et al. Neurology 2026;107:e218545.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

El Mahdaoui S, Pontieri L, Romme Christensen J, Alabdalridha H, et al. Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. Neurology 2026;107:e218545.
PMID: 42832743